영아 영축 치료제 시장 : 세계 산업 규모, 점유율, 동향, 기회 및 예측 - 치료 분류별, 약제 유형별(비가바트린, 부신피질 자극 호르몬, 기타), 투여량별, 지역별 세분화 및 경쟁 구도(2020-2030년)
Infantile Spasm Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Therapeutic Class, By Drug Type (Vigabatrin, Adrenocorticotropic Hormone, Others ), By Dosage, by Region, and Competition, 2020-2030F
상품코드:1879233
리서치사:TechSci Research
발행일:2025년 11월
페이지 정보:영문 182 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 영아 영축 치료제 시장은 2024년에 33억 2,000만 달러로 평가되었고, 2030년까지 연평균 복합 성장률(CAGR) 4.04%로 성장하여 42억 1,000만 달러에 이를 것으로 예측됩니다.
영아 경련 치료제는 영아에게 자주 집단적으로 발생하는 단시간의 급격한 근육 수축이 특징인 심각하고 희귀한 간질성 뇌질환인 영아 경련을 치료하기 위해 특별히 개발된 의약품으로 구성되어 있습니다. 주요 시장 성장 요인으로는 전 세계적인 질환에 대한 인식 개선, 조기 발견을 가능하게 하는 진단 연구 방법의 발전, 그리고 이 질환에 따른 심각한 신경 발달 후퇴를 예방하기 위한 중요한 미충족 수요를 들 수 있습니다.
시장 개요
예측 기간
2026-2030년
시장 규모 : 2024년
33억 2,000만 달러
시장 규모 : 2030년
42억 1,000만 달러
CAGR : 2025-2030년
4.04%
성장 속도가 가장 빠른 부문
항경련제
최대 시장
북미
주요 시장 성장 촉진요인
주요 시장 과제
주요 시장 동향
목차
제1장 개요
제2장 조사 방법
제3장 주요 요약
제4장 고객의 소리
제5장 세계의 영아 영축 치료제 시장 전망
시장 규모와 예측
금액별
시장 점유율과 예측
치료 분류별(항경련제, 코르티코스테로이드, 기타)
약제 유형별(비가바트린, 부신피질 자극 호르몬, 기타( 제III상))
제형별(고형, 액제)
지역별
기업별(2024년)
시장 맵
제6장 북미의 영아 영축 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
북미 : 국가별 분석
미국
캐나다
멕시코
제7장 유럽의 영아 영축 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
유럽 : 국가별 분석
독일
프랑스
영국
이탈리아
스페인
제8장 아시아태평양의 영아 영축 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
아시아태평양 : 국가별 분석
중국
인도
일본
한국
호주
제9장 중동 및 아프리카의 영아 영축 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
중동 및 아프리카 : 국가별 분석
사우디아라비아
아랍에미리트(UAE)
남아프리카공화국
제10장 남미의 영아 영축 치료제 시장 전망
시장 규모와 예측
시장 점유율과 예측
남미 : 국가별 분석
브라질
콜롬비아
아르헨티나
제11장 시장 역학
성장 촉진요인
과제
제12장 시장 동향과 발전
인수합병(M&A)
제품 출시
최근 동향
제13장 세계의 영아 영축 치료제 시장 : SWOT 분석
제14장 Porter의 Five Forces 분석
업계내 경쟁
신규 참여 가능성
공급업체의 힘
고객의 힘
대체품의 위협
제15장 경쟁 구도
Anavex Life Sciences Corp.
H. Lundbeck A/S
Catalyst Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Travere Therapeutics, Inc.
Valerion Therapeutics LLC
ORPHELIA Pharma
Novartis AG
Sanofi SA
Pfizer Inc.
제16장 전략적 제안
제17장 회사 소개 및 면책조항
LSH
영문 목차
영문목차
The Global Infantile Spasm Therapeutics Market , valued at USD 3.32 Billion in 2024, is projected to experience a CAGR of 4.04% to reach USD 4.21 Billion by 2030. Infantile spasm therapeutics comprise pharmaceutical agents specifically developed to treat infantile spasms, a severe and rare epileptic encephalopathy characterized by brief, abrupt muscle contractions often occurring in clusters in infants. Main market growth drivers include increasing global disease awareness, advancements in diagnostic methodologies enabling earlier detection, and the critical unmet medical need to prevent severe neurodevelopmental regression associated with the condition.
Market Overview
Forecast Period
2026-2030
Market Size 2024
USD 3.32 Billion
Market Size 2030
USD 4.21 Billion
CAGR 2025-2030
4.04%
Fastest Growing Segment
Anticonvulsants
Largest Market
North America
Key Market Drivers
The increasing prevalence of infantile spasms substantially drives the therapeutics market by expanding the treatable patient population. Improved diagnostic techniques and heightened awareness among medical professionals and caregivers facilitate earlier detection of these severe epileptic encephalopathies. Prompt diagnosis is critical for mitigating long-term neurodevelopmental consequences. According to data presented at the American Epilepsy Society in December 2024, from a cohort study, incidental diagnosis of Infantile Epileptic Spasms Syndrome (IESS) was observed in 29% of patients. This demonstrates how proactive screening brings more cases into the treatment pathway, directly fueling market demand.
Key Market Challenges
A significant challenge impeding the expansion of the Global Infantile Spasm Therapeutics Market stems from the high cost associated with existing first-line treatments, such as adrenocorticotropic hormone, coupled with often complex reimbursement processes. This financial burden critically limits patient access to timely and effective therapies, particularly in regions with developing healthcare infrastructures. The inability of patients to afford or readily obtain these essential medications directly translates into under-treatment or delayed intervention.
Key Market Trends
The Global Infantile Spasm Therapeutics Market is significantly shaped by the emergence of precision and genetically-targeted therapies. This trend represents a fundamental shift towards developing treatments that address the specific underlying genetic causes of infantile spasms, moving beyond broad-spectrum approaches. This individualized therapeutic strategy holds the promise of improved efficacy and reduced side effects for distinct patient populations. According to the American Epilepsy Society (AES), a study presented at their 2024 annual meeting highlighted that studies including non-European participants, representing only 16% of 68 genome-wide association studies, identified 58% of significant Single Nucleotide Polymorphisms linked to epilepsy. This demonstrates the impact of genetic research in uncovering crucial insights for targeted interventions.
Key Market Players
Anavex Life Sciences Corp.
H. Lundbeck A/S
Catalyst Pharmaceuticals, Inc.
Jazz Pharmaceuticals, Inc.
Travere Therapeutics, Inc.
Valerion Therapeutics LLC
ORPHELIA Pharma
Novartis AG
Sanofi SA
Pfizer Inc.
Report Scope:
In this report, the Global Infantile Spasm Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
Infantile Spasm Therapeutics Market , By Therapeutic Class:
Anticonvulsants
Corticosteroids
Others
Infantile Spasm Therapeutics Market , By Drug Type:
Vigabatrin
Adrenocorticotropic Hormone
Others (Phase III)
Infantile Spasm Therapeutics Market , By Dosage:
Solid
Liquid
Infantile Spasm Therapeutics Market , By Region:
North America
United States
Canada
Mexico
Asia Pacific
China
India
Japan
Australia
South Korea
Europe
France
United Kingdom
Italy
Germany
Spain
South America
Brazil
Argentina
Colombia
Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies presents in the Global Infantile Spasm Therapeutics Market .
Available Customizations:
Global Infantile Spasm Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
Detailed analysis and profiling of additional market players (up to five).
Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Infantile Spasm Therapeutics Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Therapeutic Class (Anticonvulsants, Corticosteroids, Others)
5.2.2. By Drug Type (Vigabatrin, Adrenocorticotropic Hormone, Others (Phase III))
5.2.3. By Dosage (Solid, Liquid)
5.2.4. By Region
5.2.5. By Company (2024)
5.3. Market Map
6. North America Infantile Spasm Therapeutics Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Therapeutic Class
6.2.2. By Drug Type
6.2.3. By Dosage
6.2.4. By Country
6.3. North America: Country Analysis
6.3.1. United States Infantile Spasm Therapeutics Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Therapeutic Class
6.3.1.2.2. By Drug Type
6.3.1.2.3. By Dosage
6.3.2. Canada Infantile Spasm Therapeutics Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Therapeutic Class
6.3.2.2.2. By Drug Type
6.3.2.2.3. By Dosage
6.3.3. Mexico Infantile Spasm Therapeutics Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Therapeutic Class
6.3.3.2.2. By Drug Type
6.3.3.2.3. By Dosage
7. Europe Infantile Spasm Therapeutics Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Therapeutic Class
7.2.2. By Drug Type
7.2.3. By Dosage
7.2.4. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Infantile Spasm Therapeutics Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Therapeutic Class
7.3.1.2.2. By Drug Type
7.3.1.2.3. By Dosage
7.3.2. France Infantile Spasm Therapeutics Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Therapeutic Class
7.3.2.2.2. By Drug Type
7.3.2.2.3. By Dosage
7.3.3. United Kingdom Infantile Spasm Therapeutics Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Therapeutic Class
7.3.3.2.2. By Drug Type
7.3.3.2.3. By Dosage
7.3.4. Italy Infantile Spasm Therapeutics Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Therapeutic Class
7.3.4.2.2. By Drug Type
7.3.4.2.3. By Dosage
7.3.5. Spain Infantile Spasm Therapeutics Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Therapeutic Class
7.3.5.2.2. By Drug Type
7.3.5.2.3. By Dosage
8. Asia Pacific Infantile Spasm Therapeutics Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Therapeutic Class
8.2.2. By Drug Type
8.2.3. By Dosage
8.2.4. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Infantile Spasm Therapeutics Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Therapeutic Class
8.3.1.2.2. By Drug Type
8.3.1.2.3. By Dosage
8.3.2. India Infantile Spasm Therapeutics Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Therapeutic Class
8.3.2.2.2. By Drug Type
8.3.2.2.3. By Dosage
8.3.3. Japan Infantile Spasm Therapeutics Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Therapeutic Class
8.3.3.2.2. By Drug Type
8.3.3.2.3. By Dosage
8.3.4. South Korea Infantile Spasm Therapeutics Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Therapeutic Class
8.3.4.2.2. By Drug Type
8.3.4.2.3. By Dosage
8.3.5. Australia Infantile Spasm Therapeutics Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Therapeutic Class
8.3.5.2.2. By Drug Type
8.3.5.2.3. By Dosage
9. Middle East & Africa Infantile Spasm Therapeutics Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Therapeutic Class
9.2.2. By Drug Type
9.2.3. By Dosage
9.2.4. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Infantile Spasm Therapeutics Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Therapeutic Class
9.3.1.2.2. By Drug Type
9.3.1.2.3. By Dosage
9.3.2. UAE Infantile Spasm Therapeutics Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Therapeutic Class
9.3.2.2.2. By Drug Type
9.3.2.2.3. By Dosage
9.3.3. South Africa Infantile Spasm Therapeutics Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Therapeutic Class
9.3.3.2.2. By Drug Type
9.3.3.2.3. By Dosage
10. South America Infantile Spasm Therapeutics Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Therapeutic Class
10.2.2. By Drug Type
10.2.3. By Dosage
10.2.4. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Infantile Spasm Therapeutics Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Therapeutic Class
10.3.1.2.2. By Drug Type
10.3.1.2.3. By Dosage
10.3.2. Colombia Infantile Spasm Therapeutics Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Therapeutic Class
10.3.2.2.2. By Drug Type
10.3.2.2.3. By Dosage
10.3.3. Argentina Infantile Spasm Therapeutics Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Therapeutic Class
10.3.3.2.2. By Drug Type
10.3.3.2.3. By Dosage
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Infantile Spasm Therapeutics Market : SWOT Analysis
